Genmab — Januar 2019

[Solsen]

Jeg tror også vi hænger lidt i bremsen mht salget indtil sc er på banen. Men så ligger $10bn lige for

[E_L]

@peter12 they mentioned it a bit in the Q&A. no surprises. nice that they mention Dara first again when talking about blockbusters etc

[Bulder]

Did they say anything about penetration of frontline up against RVd?

[peter12]

Knock your socks off ... nej mener det ikke, men webcastet q/a
ligger på deres side nu

[E_L]

it wasn't that specific; they mainly mentioned how SC would benefit to getting to 1st line (and that fact is undervalued according to her
)

[E_L]

seekingalpha already has it, but only for subscribers https://seekingalpha.com/article/4035409-johnson-and-johnsons-jnj-management-presents-jpmorgan-health-care-conference-transcript

[jkj]

Næste modstandsområde 1144

[E_L]

what do you see there? I am looking at the august high 1125 and small ab=cd at 1128 ( 786,2 1016 AB=CD 898,4 1128)

[E_L]

then july high 1150.5

[Helge_LarsenPI-redaktør]

Brud på 1120 er vist nok tegn på at nedtrend er vendt til uptrend.

[Helge_LarsenPI-redaktør]

1120-1130

[jkj]

I look here ELhttps://www.marketscreener.com/GENMAB-1412914/charts/?iCStream=1

[E_L]

you could also argue the small double bottom at 988/989 targets 1197

[E_L]

but it is all a bit premature in this market

[Helge_LarsenPI-redaktør]

Just a moment...

(www.proinvestor.com)

[Plimsoller]

Vi kan vel efterhånden se bort fra RTOR som en mulighed?

[StockBull]

HarJNJ ikke gentagende gange sagt ansøgningen bliver sendt i Januar 2019

[StockBull]

Hvad ser i som Genmabs triggers for 2019. Jeg vil mene. 2019 Guidance, mod forventning RTOR godkendelse, Griffin data, asclepios data og phase III data SubQ (columba)

[StockBull]

derudover JNJ resultat for 2018

[StockBull]

og MorphoSys patent sag kan vel også give et lille nok op eller stort hak ned